EFTR.png
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
24 juin 2024 07h00 HE | eFFECTOR Therapeutics, Inc.
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) today announced that the Company has terminated its employees and will...
EFTR.png
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
20 mai 2024 08h30 HE | eFFECTOR Therapeutics, Inc.
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors...
EFTR.png
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
09 mai 2024 16h01 HE | eFFECTOR Therapeutics, Inc.
Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024 Raised $15.0 million in gross proceeds from registered direct financing, extending cash runway...
EFTR.png
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
09 avr. 2024 08h00 HE | eFFECTOR Therapeutics, Inc.
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator...
EFTR.png
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
04 avr. 2024 08h30 HE | eFFECTOR Therapeutics, Inc.
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator...
EFTR.png
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
25 mars 2024 16h01 HE | eFFECTOR Therapeutics, Inc.
Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in early April 2024 Median progression free...
EFTR.png
eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
05 févr. 2024 08h30 HE | eFFECTOR Therapeutics, Inc.
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors...
EFTR.png
eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
29 janv. 2024 16h05 HE | eFFECTOR Therapeutics, Inc.
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) (the “Company”), a leader in the development of selective translation...
EFTR.png
eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
25 janv. 2024 08h00 HE | eFFECTOR Therapeutics, Inc.
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) (the “Company”), a leader in the development of selective translation...
EFTR.png
eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
09 janv. 2024 08h05 HE | eFFECTOR Therapeutics, Inc.
-  Summary of development progress for tomivosertib and zotatifin and a preview of anticipated 2024 milestones- -  Review of recently announced interim data from dose escalation and Phase 2 expansion...